Lymphoseek Approved for Diagnosing Cancer Severity
FRIDAY, June 13, 2014 (HealthDay News) -- U.S. Food and Drug Administration approval for the Lymphoseek imaging agent (technetium 99m tilmanocept) has been expanded to include helping doctors determine if a type of cancer called squamous cell carcinoma has spread to the head and neck, and to what extent, the FDA said Friday.
The injected agent was first approved in 2013 to help doctors identify lymph nodes associated with breast cancer or melanoma skin cancer, the agency said in a news release.
For the newly approved use, the agent was evaluated in clinical study of 85 people with squamous cell carcinoma of the lip, mouth or skin. The most common side effects noted were injection-site pain and irritation.
Lymphoseek is marketed by Navidea Biopharmaceuticals, based in Dublin, Ohio.
The FDA has more about this approval.Related Articles
- FDA Panel: Limit Testosterone Drug Use
September 18, 2014
- DNA Blood Test Might Identify Status of Prostate Cancer
September 17, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2013 HealthDay. All rights reserved.